Severity on COVID-19 and systemic arterial hypertension: The new hypotheses
Downloads
References
Fang, L, Karakiulakis, G, Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The Lancet. Respiratory Medicine. 2020; 8(4): e21.
de Abajo, FJ, Rodríguez-Martín, S, Lerma, V, Mejía-Abril, G, Aguilar, M, García-Luque, A, Elvira, C. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. The Lancet. 2020.
Tadzic, R, Mihalj, M, Vcev, A, Ennen, J, Tadzic, A, Drenjancevic-Peric, I. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney and Blood Pressure Research. 2013; 37(2-3):103-15.
Noris, M, Benigni, A, Remuzzi, G. The case of Complement activation in COVID-19 multiorgan impact. Kidney International. 2020.
Horby, P, Lim, WS, Emberson, JR, Mafham, M, Bell, JL, Linsell, L, Landray, MJ. Dexamethasone in hospitalized patients with Covid-19-preliminary report. The New England journal of medicine. 2020.
Jilma, B, Blann, AD, Stohlawetz, P, Eichler, HG, Kautzky-Willer, A, Wagner, OF. Dexamethasone lowers circulating E-selectin and ICAM-1 in healthy men. Journal of Laboratory and Clinical Medicine. 2000; 135(3): 270-74.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Journal of Multiprofessional Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This work is licensed under a Creative Commons License - Attribution-NonCommercial-NoDerivatives 4.0 International.
